van Veldhuisen, Eran
Klompmaker, Sjors
Janssen, Quisette P.
Hilal, Mohammed Abu
Alseidi, Adnan
Balduzzi, Alberto
Balzano, Gianpaolo
Bassi, Claudio
Berrevoet, Frederik
Bonds, Morgan
Busch, Olivier R.
Butturini, Giovanni
Conlon, Kevin C.
Frigerio, Isabella M.
Fusai, Giuseppe K.
Gagnière, Johan
Griffin, Oonagh
Hackert, Thilo
Halimi, Asif
Keck, Tobias
Kleeff, Jörg
Klaiber, Ulla
Labori, Knut J.
Lesurtel, Mickael
Malleo, Giuseppe
Marino, Marco V.
Molenaar, I. Quintus
Mortensen, Michael B.
Nikov, Andrej
Pagnanelli, Michele
Pandé, Rupaly
Pfeiffer, Per
Pietrasz, Daniel
Rangelova, Elena
Roberts, Keith J.
Cunha, Antonio Sa
Salvia, Roberto
Strobel, Oliver
Tarvainen, Timo
Wilmink, Johanna W.
Koerkamp, Bas Groot
Besselink, Marc G.
Sauvanet, Alain
Marthey, Lysiane
Marthey, Lysiane
Laurent, Christophe
Régenet, Nicolas
Coriat, Romain
Taieb, Julien
Turini, Olivier
Dubray, Vincent
Bourdariat, Raphael
Bachet, Jean Baptiste
Schwartz, Lilian
,
Funding for this research was provided by:
KWF Kankerbestrijding (2014-7244)
Article History
Received: 2 June 2021
Accepted: 25 July 2022
First Online: 20 December 2022
Disclosure
: Hanneke Wilmink served in an advisory role for Shire, Celgene, Servier, and Merck and received research funding from Servier, Halozyme, Novartis, Celgene, Astra Zeneca, Pfizer, Roche, and Merck. The remaining authors have no conflicts of interest.